Plant-inspired drug discovery: New strategies for new leads

Planta Medica ◽  
2014 ◽  
Vol 80 (16) ◽  
Author(s):  
N De Tommasi
Antioxidants ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 367
Author(s):  
Andrea Bacci ◽  
Massimiliano Runfola ◽  
Simona Sestito ◽  
Simona Rapposelli

The complex network of malfunctioning pathways occurring in the pathogenesis of neurodegenerative diseases (NDDs) represents a huge hurdle in the development of new effective drugs to be used in therapy. In this context, redox reactions act as crucial regulators in the maintenance of neuronal microenvironment homeostasis. Particularly, their imbalance results in the severe compromising of organism’s natural defense systems and subsequently, in the instauration of deleterious OS, that plays a fundamental role in the insurgence and progress of NDDs. Despite the huge efforts in drug discovery programs, the identification process of new therapeutic agents able to counteract the relentless progress of neurodegenerative processes has produced low or no effective therapies. Consequently, a paradigm-shift in the drug discovery approach for these diseases is gradually occurring, paving the way for innovative therapeutical approaches, such as polypharmacology. The aim of this review is to provide an overview of the main pharmacological features of most promising nature-based scaffolds for a possible application in drug discovery, especially for NDDs, highlighting their multifaceted effects against OS and neuronal disorders.


Blood ◽  
2011 ◽  
Vol 117 (25) ◽  
pp. 6747-6755 ◽  
Author(s):  
Mahadeo A. Sukhai ◽  
Paul A. Spagnuolo ◽  
Scott Weir ◽  
James Kasper ◽  
Lavonne Patton ◽  
...  

Abstract Advancing novel therapeutic agents for the treatment of malignancy into the marketplace is an increasingly costly and lengthy process. As such, new strategies for drug discovery are needed. Drug repurposing represents an opportunity to rapidly advance new therapeutic strategies into clinical trials at a relatively low cost. Known on-patent or off-patent drugs with unrecognized anticancer activity can be rapidly advanced into clinical testing for this new indication by leveraging their known pharmacology, pharmacokinetics, and toxicology. Using this approach, academic groups can participate in the drug discovery field and smaller biotechnology companies can “de-risk” early-stage drug discovery projects. Here, several scientific approaches used to identify drug repurposing opportunities are highlighted, with a focus on hematologic malignancies. In addition, a discussion of the regulatory issues that are unique to drug repurposing and how they impact developing old drugs for new indications is included. Finally, the mechanisms to enhance drug repurposing through increased collaborations between academia, industry, and nonprofit charitable organizations are discussed.


2012 ◽  
Vol 140 (1) ◽  
pp. 197-201 ◽  
Author(s):  
Ulysses Paulino Albuquerque ◽  
Marcelo Alves Ramos ◽  
Joabe Gomes Melo

2021 ◽  
Vol 64 (7) ◽  
pp. 3493-3507
Author(s):  
Junping Pei ◽  
Guan Wang ◽  
Lu Feng ◽  
Jifa Zhang ◽  
Tingting Jiang ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Jian-Long Zhang ◽  
Wen-Li Tang ◽  
Qing-Rong Huang ◽  
You-Zhi Li ◽  
Mao-Lian Wei ◽  
...  

Fungi play an irreplaceable role in drug discovery in the course of human history, as they possess unique abilities to synthesize diverse specialized metabolites with significant medicinal potential. Trichoderma are well-studied filamentous fungi generally observed in nature, which are widely marketed as biocontrol agents. The secondary metabolites produced by Trichoderma have gained extensive attention since they possess attractive chemical structures with remarkable biological activities. A large number of metabolites have been isolated from Trichoderma species in recent years. A previous review by Reino et al. summarized 186 compounds isolated from Trichoderma as well as their biological activities up to 2008. To update the relevant list of reviews of secondary metabolites produced from Trichoderma sp., we provide a comprehensive overview in regard to the newly described metabolites of Trichoderma from the beginning of 2009 to the end of 2020, with emphasis on their chemistry and various bioactivities. A total of 203 compounds with considerable bioactivities are included in this review, which is worth expecting for the discovery of new drug leads and agrochemicals in the foreseeable future. Moreover, new strategies for discovering secondary metabolites of Trichoderma in recent years are also discussed herein.


Sign in / Sign up

Export Citation Format

Share Document